NASDAQ · Biotechnology · USD
Kyverna Therapeutics, Inc. (KYTX) Stock Analysis
Kyverna Therapeutics, Inc. (KYTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
KYTX Key Statistics
As of Oct 21, 2026Trading
- Open
- $6.15
- Previous Close
- $6.04
- Day's Range
- 5.80–6.30
- 52-Week Range
- 5.61–13.67
- Volume
- 829.05K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.06
Valuation
- Market Cap
- $361.17M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.93
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$161.31M
- Shares Outstanding
- 61.84M
- 1-Year Return
- −18.21%
Dividend and dates
- Earnings Date
- November 11, 2026estimated
- Avg Volume
- 832.46K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, KYTX closed at $5.84, −18.21% over 1 year.
Kyverna Therapeutics, Inc. (KYTX) has a market capitalization of $361.17M.
In fiscal 2025, KYTX reported revenue of $0.00.
KYTX Stock Return by Calendar Year
Kyverna Therapeutics, Inc. (KYTX) return since Feb 2024: what $10,000 became
- 1 year
- $10,000 $8,179
- −18.21%
- Since Feb 2024
- $10,000 $1,940
- −80.60%
If you had invested $10,000 in Kyverna Therapeutics, Inc. (KYTX) at the close on February 9, 2024, the earliest close on record here, it would have been worth $1,940 at the close on October 21, 2026: −80.60% in total, −45.56% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −37.87% |
| 2025 | +151.34% |
| 2024 (partial year) | −87.57% |
As of October 21, 2026.
KYTX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$161.31M | — |
| 2024 | $0.00 | −$127.48M | — |
| 2023 | $0.00 | −$60.37M | — |
| 2022 | $7.03M | −$28.89M | −411.3% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$169.83M | −$161.31M | — |
| 2024 | $0.00 | — | −$142.60M | −$127.48M | — |
| 2023 | $0.00 | — | −$62.41M | −$60.37M | — |
| 2022 | $7.03M | — | −$29.38M | −$28.89M | −411.3% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
YahooKyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
YahooKyverna Therapeutics To Demonstrate Two Abstracts For Presentation At MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting
BenzingaKYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
StocktwitsKyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow
SeekingAlphaKyverna stock jumps on positive one-year therapy data
Yahoo
All 18 articles ↓Show fewer ↑
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
SeekingAlphaKyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions
BenzingaKyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
InvestorsHubKyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
YahooKyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct
BenzingaKyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SeekingAlphaKyverna Therapeutics to Present at Upcoming Investor Conferences
YahooKyverna Therapeutics: Market Holding Flat Despite Progress To Approval
SeekingAlphaKyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
BenzingaKyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement
SeekingAlphaKyverna Therapeutics shares are trading higher after the company and ElevateBio announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel, autologous CD19-directed CAR T-cell therapy.
BenzingaKyverna Therapeutics, ElevateBio Announce Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B